Arena Investors’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Arena Investors’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-180	Closed	-$1.8K	–	122
2022 Q3	$1.8K	Hold	180	–	–	﹤0.01%	155
2022 Q2	$2K	Hold	180	–	–	﹤0.01%	164
2022 Q1	$2K	Buy	+180	New	+$1.77K	﹤0.01%	106

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Arena Investors's EUCR Position: Q4 2022 in Review

Arena Investors sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 180 shares — an estimated $1.8K sold.

Arena Investors first reported a position in EUCR in Q1 2022 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Arena Investors reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Arena Investors sold 180 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1.8K.
Arena Investors first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2022 and held it in 3 quarters.
Arena Investors's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $2K in Q2 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Arena Investors's 13F filing for Q4 2022, filed 14 Feb 2023.